Laura Bio PicProf. Laura van ’t Veer PhD is co-founder of Agendia and serves as its Chief Research Officer. As one of the world’s leading innovators in cancer diagnostics, she is widely recognized as a pioneer in the field of personalized medicine, also known as precision medicine. She has a 20-year track record in molecular oncology research, which includes more than 230 scientific publications and prestigious awards for her contributions to breast cancer care.

Dr. van ‘t Veer is best known for work stemming from a discovery she and her team made at the Netherlands Cancer Institute (NKI). They established that a specific DNA signature made up of 70 genes distinguished whether breast cancer tumors had a low or high risk of recurrence. After patenting their innovation, she and research partner René Bernards founded Agendia and launched the MammaPrint test.

In 2010, Dr. van ‘t Veer was appointed Professor of Laboratory Medicine and Director of Applied Genomics at the University of California San Francisco. She is also the former head of the NKI’s DNA-diagnostic laboratory. She was awarded a 2014 European Union Prize for Women Innovators that acknowledges the ways MammaPrint has helped transform breast cancer care. (For video, click here.)  In 2015, the European Patent Office (EPO) recognized MammaPrint’s impact on breast cancer diagnostics by honouring Dr. van ‘t Veer with a European Inventor Award. To see video from the EPO about Dr. van ‘t Veer’s work, click here.

Laura van ’t Veer (Netherlands) winner of the European Inventor Award 2015 in the SMEs category, with EU Commissioner Elżbieta Bieńkowska and EPO President Battistelli at the ceremony at the Palais Brongniart in Paris on 11 June.
Laura van ’t Veer (Netherlands) winner of the European Inventor Award 2015 in the SMEs category, with EU Commissioner Elżbieta Bieńkowska and EPO President Battistelli at the ceremony at the Palais Brongniart in Paris on 11 June.